Press Release

Global Circulating Tumor Cells Market Size To Reach US$ 2.5 Bn By 2026 At A CAGR Of 18.3%

Circulating tumor cells is booming on account of the escalating awareness amongst individuals for the advantages of maintaining a decent health and the increasing demand for high quality healthcare services. With the increasing prevalence of diseases across the globe, people are opting for products that assist them to stay fit and are investing more on healthcare services. Circulating tumor cells are celss that are released from primary or metastatic tumors into circulation. Though, these cells are rare in most cancer patients, recent improvements in circulating tumor cells capture, enrichment, and detection technologies have substantially improved the clinical feasibility of evaluating these cells to examine tumor progression and therapeutic responsiveness. Circulating tumor cells detection allows for the identification of those lung cancer patients with a higher risk of disease recurrence, possibly allowing clinicians to define which patients are likely to benefit from adjuvant treatment post-surgery. Following these promising developments, the Global Circulating Tumor Cells Market is estimated to see healthy growth, pegged at a CAGR of around 18.3% throughout the forecast period 2020-2026.

GET SAMPLE PAGES @ https://www.reportocean.com/industry-verticals/sample-request?report_id=QY4729

Surgery is expected to alter metabolite profiles in lung cancer patients such that metabolomic studies may permit for a detailed understanding of these operation. Metabolomic studies allow for the simultaneous study of thousands of unique endogenous metabolites in a given biological sample. These metabolomic methods have allowed for the detection of cancer-associated biomarkers and/or biomarkers linked with therapeutic responsiveness, thus, permitting for the monitoring of these biomarkers to better understand disease progression.

The advent of clinical resistance in recurrently treated cancers increases from the primary tumor’s capability to utilize genome instability to escape, adapt, and progress. Triple negative breast cancer operates as a good option of such a response indicating poor clinical outcome owing to a high rate of cellular heterogeneity resultant in metastatic relapse. Newly developed liquid biopsy technologies are expected to offer potential to achieve this goal. Liquid biopsies have a capability to identify circulating tumor cells and cell free tumor products, such as cell free DNA, circulating tumor DNA, and exosomes, that have avoided from the primary tumor, allowing molecular characterization, and the potential for clinicians to tailor precision medicine to the emergent therapy resistant cells. As circulating tumor cells play such a key role in the establishment of metastasis, several researchers support for utilizing them in the clinical setting. Circulating tumor cells enumeration has served as a prognostic marker in metastatic breast cancer since the beginning of the twenty-first century, with CellSearch being the first test system to be authorized by the FDA (Food and Drug Administration) for use in metastatic breast cancer.

Segmentation Overview of the Global Circulating Tumor Cells Market

The circulating tumor cells market is segmented into technology, application, product, and specimen. These major market segments are further categorized into various sub-segments to study the market in detail.

By Technology Outlook (CTC Detection & Enrichment Methods (Immunocapture (Label-based), Size-based Separation (Label-free), Density-based Separation (Label-free), and Combined Methods (Label-free)), CTC Direct Detection Methods (SERS, Microscopy, and Others), CTC Analysis)

By Application Outlook (Clinical/Liquid Biopsy, Research)

By Product Outlook (Kits & Reagents, Blood Collection Tubes, and Devices or Systems)

By Specimen Outlook (Blood, Bone Marrow, Others)

Key Players Insights

Greiner Bio-One, BioFluidica, Bio-Techne Corporation, Rarecells Diagnostics, QIAGEN, ScreenCell, Menarini Silicon Biosystems, Sysmex Corporation, Miltenyi Biotec, Fluxion Biosciences, and Biocept, Inc., among others, are some key market players included in the research study of the global circulating tumor cells market.

Feel Free To Ask Question Before Purchasing The Report @ https://www.reportocean.com/industry-verticals/sample-request?report_id=QY4729

About Report Ocean:

We are the best market research reports provider in the industry. Report Ocean believe in providing the quality reports to clients to meet the top line and bottom line goals which will boost your market share in today’s competitive environment. Report Ocean is “one-stop solution” for individuals, organizations, and industries that are looking for innovative market research reports.

Get in Touch with Us:

Nishi Sharma

Email: [email protected]

Address: 500 N Michigan Ave, Suite 600, Chicago, IIIinois 60611 – UNITED STATES

Tel: +1 888 212 3539 (US – TOLL FREE)

Website: https://www.reportocean.com/

Tags: , , , , ,

See Campaign: https://www.reportocean.com/industry-verticals/sample-request?report_id=QY4729
Contact Information:
+1 888 212 3539 (US – TOLL FREE)

Tags:
, IPS, Menafn, Reportedtimes, Research Newswire, English

image

Contact Information:

+1 888 212 3539 (US – TOLL FREE)